Wells Fargo Maintains Equal-Weight on Editas Medicine, Lowers Price Target to $9
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Yanan Zhu has maintained an Equal-Weight rating on Editas Medicine but significantly lowered the price target from $27 to $9.
October 23, 2024 | 2:24 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Wells Fargo has maintained an Equal-Weight rating on Editas Medicine but reduced the price target from $27 to $9, indicating a less optimistic outlook.
The significant reduction in the price target from $27 to $9 by Wells Fargo suggests a negative outlook on Editas Medicine's future performance. This could lead to a decrease in investor confidence and a potential drop in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100